More DCAT Value Chain Insights

In-depth analysis of the critical issues impacting the full spectrum of the pharmaceutical manufacturing value chain.

Fortune released its annual list of the Fortune 500 companies, which rank the companies in the US with the largest revenues. So how did pharmaceutical companies and suppliers score in the 2017 rankings? Johnson & Johnson, the pharmaceutical,...

How can pharmaceutical companies and suppliers best partner to achieve cost-efficiencies and drive value? A preview of DCAT Sharp Sourcing, to be held June 26, highlights best practices. The program features collaborative approaches with insight...

Takeda Pharmaceutical’s proposed $62-billion acquisition of Shire provides Takeda with geographic and product diversification. So what would a combined Takeda/Shire be? The acquisition of Shire would strengthen Takeda’s position in markets outside...

Small molecules still dominate late-stage pipelines and remain significant in early-stage development as well. So how does that translate to contract manufacturers of advanced intermediates and small-molecule active pharmaceutical ingredients...

The US is the largest pharmaceutical market in the world, but where does it stand in trade? A new report by the Office of the United States Trade Representative highlights concerns regarding intellectual property protection and enforcement and...

Responsible sourcing for minerals from conflict-ridden areas is an important consideration in many industries, particularly the electronics and computer industries, but it is also an issue in the pharmaceutical and chemical industries where...

Spending on all US medicines increased only 0.6% in 2017 to $324 billion on a net basis due to greater generic volume, larger manufacturer discounts, and increasing coupon use, according to a recent analysis by the IQVIA Institute for Human Data...